Skip to main content
KPT-330 has antitumour activity against non-small cell lung cancer.
- Author(s): Sun, H;
- Hattori, N;
- Chien, W;
- Sun, Q;
- Sudo, M;
- E-Ling, GL;
- Ding, L;
- Lim, SL;
- Shacham, S;
- Kauffman, M;
- Nakamaki, T;
- Koeffler, HP
- et al.
Published Web Locationhttps://doi.org/10.1038/bjc.2014.260
BackgroundWe investigated the biologic and pharmacologic activities of a chromosome region maintenance 1 (CRM1) inhibitor against human non-small cell lung cancer (NSCLC) cells both in vitro and in vivo.
MethodsThe in vitro and in vivo effects of a novel CRM1 inhibitor (KPT-330) for a large number of anticancer parameters were evaluated using a large panel of 11 NSCLC cell lines containing different key driver mutations. Mice bearing human NSCLC xenografts were treated with KPT-330, and tumour growth was assessed.
ResultsKPT-330 inhibited proliferation and induced cell cycle arrest and apoptosis-related proteins in 11 NSCLC cells lines. Moreover, the combination of KPT-330 with cisplatin synergistically enhanced the cell kill of the NSCLC cells in vitro. Human NSCLC tumours growing in immunodeficient mice were markedly inhibited by KPT-330. Also, KPT-330 was effective even against NSCLC cells with a transforming mutation of either exon 20 of EGFR, TP53, phosphatase and tensin homologue, RAS or PIK3CA, suggesting the drug might be effective against a variety of lung cancers irrespective of their driver mutation.
ConclusionsOur results support clinical testing of KPT-330 as a novel therapeutic strategy for NSCLC.
For improved accessibility of PDF content, download the file to your device.